Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international …

E Vidal-Petiot, I Ford, N Greenlaw, R Ferrari, KM Fox… - The Lancet, 2016 - thelancet.com
Background The optimum blood pressure target in hypertension remains debated,
especially in coronary artery disease, given concerns for reduced myocardial perfusion if …

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

JR Petrie, N Chaturvedi, I Ford… - The lancet Diabetes & …, 2017 - thelancet.com
Background Metformin might reduce insulin requirement and improve glycaemia in patients
with type 1 diabetes, but whether it has cardiovascular benefits is unknown. We aimed to …

[HTML][HTML] Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint …

IS Mackenzie, CJ Hawkey, I Ford, N Greenlaw… - The Lancet, 2022 - thelancet.com
Background Allopurinol is a urate-lowering therapy used to treat patients with gout. Previous
studies have shown that allopurinol has positive effects on several cardiovascular …

[HTML][HTML] Aliskiren, enalapril, or aliskiren and enalapril in heart failure

JJV McMurray, H Krum, WT Abraham… - … England Journal of …, 2016 - Mass Medical Soc
Background Among patients with chronic heart failure, angiotensin-converting–enzyme
(ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such …

Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial

AD Ormerod, KS Thomas, FE Craig, E Mitchell… - bmj, 2015 - bmj.com
Objective To determine whether ciclosporin is superior to prednisolone for the treatment of
pyoderma gangrenosum, a painful, ulcerating skin disease with a poor evidence base for …

Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry

PG Steg, N Greenlaw, JC Tardif, M Tendera… - European heart …, 2012 - academic.oup.com
Aims Men and women differ in terms of presentation and management in coronary artery
disease (CAD). Whether these differences translate into different clinical outcomes in stable …

Intravenous ferric carboxymaltose in iron‐deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR‐HF trial

G Filippatos, D Farmakis, JC Colet… - European journal of …, 2013 - Wiley Online Library
Aims Therapy with iv iron in patients with chronic heart failure (CHF) and iron deficiency (ID)
improves symptoms, functional capacity, and quality of life. We sought to investigate whether …

Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the …

PG Steg, N Greenlaw, M Tendera, JC Tardif… - JAMA Internal …, 2014 - jamanetwork.com
Importance In the era of widespread revascularization and effective antianginals, the
prevalence and prognostic effect of anginal symptoms and myocardial ischemia among …

[HTML][HTML] Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised …

PR Kalra, JGF Cleland, MC Petrie, EA Thomson… - The Lancet, 2022 - thelancet.com
Background For patients with heart failure, reduced left ventricular ejection fraction and iron
deficiency, intravenous ferric carboxymaltose administration improves quality of life and …

[HTML][HTML] Heart rate and use of beta-blockers in stable outpatients with coronary artery disease

PG Steg, R Ferrari, I Ford, N Greenlaw, JC Tardif… - PloS one, 2012 - journals.plos.org
Background Heart rate (HR) is an emerging risk factor in coronary artery disease (CAD).
However, there is little contemporary data regarding HR and the use of HR-lowering …